Otitopic

Otitopic is a late-stage dry powder inhalation of aspirin company with a track record of success in pharmaceutical product drug delivery and drug device development. Asprihale® is a novel, proprietary aspirin formulation administered via a DPI, entering the bloodstream faster than oral tablets.


Visit Website

Headquarters
Otitopic LLC
10390 Santa Monica Blvd #200
Los Angeles
CA 90025
United States

Phone / Contact

T: +1 877 443 8710
E: [email protected]

Connect

Otitopic is a late-stage dry powder inhalation of aspirin company with a track record of success in pharmaceutical product drug delivery and drug device development. Asprihale® is a novel, proprietary aspirin formulation administered via a DPI, entering the bloodstream faster than oral tablets. Otitopic is on track with Asprihale® to file a US NDA in 2021/2022 for a novel drug device combination product to reduce the risk of vascular mortality in patients with suspected acute MI.

Otitopic is pioneering a new class of dry-powder inhalation in the cardiovascular medicine field, based on the company’s proprietary drug delivery platform. This patented technology leverages inhalation as the route of administration, enabling rapid inhibition of platelet aggregation, aimed at providing powerful new therapeutic capabilities.

Otitopic was founded in 2012 and is privately owned.

Articles by Otitopic

Top